Comparing serum basal and follicular fluid levels of anti-Mullerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome

ABSTRACT

The prediction of in vitro fertilization [IVF] outcomes by anti-Mllerian hormone [AMH] measurement is getting increasing attention from clinicians. This study compares the relationship between serum or intrafollicular AMH levels and IVF outcomes in women with and without polycystic ovary syndrome [PCOS]. This prospective study was carried out in two university-based fertility clinics. Serum samples were collected on cycle day 3 and follicular fluid [FF] was collected on the day of oocyte retrieval from 26 women with PCOS and 42 normo-ovulatory controls. AMH levels were measured in the samples using immunoenzymatic assay. The relationship between serum or FF AMH levels and IVF outcomes, including number of oocytes retrieved, oocyte maturation rate, fertilization rate, implantation rate, high quality grade embryo rate, and bio-chemical and clinical pregnancy rates were further assessed. Median serum basal AMH and FF AMH levels were significantly higher in the PCOS group as compared to controls, the values being 14.2 ng/mL vs. 3.2 ng/mL [P<0.001] and 8.2 ng/g protein vs. 4.7 ng/g protein [P,.01], respectively. In both groups, serum basal AMH levels showed a positive correlation with number of positive relationship between serum basal AMH levels and percentage of matured oocytes [r=0.331; P=0.32] and implantation rate [r=0.305; P=.05]. Serum basal, and not intrafollicular, AMH levels may be a good predictive factor for quantitative and qualitative IVF outcomes in normo-ovulatory, but not in PCOS patients